A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

NCT02621892 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

606

Enrollment

INDUSTRY

Sponsor class

Conditions

Constipation Predominant Irritable Bowel Syndrome

Interventions

DRUG: Tenapanor
DRUG: Placebo

Sponsor

Ardelyx